These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10392410)

  • 41. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.
    Kohlrausch FB; Gama CS; Lobato MI; Belmonte-de-Abreu P; Callegari-Jacques SM; Gesteira A; Barros F; Carracedo A; Hutz MH
    Pharmacogenet Genomics; 2008 Jul; 18(7):599-609. PubMed ID: 18551040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Study of the clinical utility of radioreceptor assay in outpatients with schizophrenia receiving high doses of neuroleptics.
    Gagné MA; Cormier H; Leblanc G; Lévesque D; Di Paolo T
    Can J Psychiatry; 1993 Oct; 38(8):534-40. PubMed ID: 7902199
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia.
    Van Dorn RA; Swanson JW; Swartz MS; Elbogen EB
    Ment Health Serv Res; 2005 Jun; 7(2):123-34. PubMed ID: 15974158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Race and tardive dyskinesia among outpatients at a CMHC.
    Glazer WM; Morgenstern H; Doucette J
    Hosp Community Psychiatry; 1994 Jan; 45(1):38-42. PubMed ID: 7907310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ethnic differences in maintenance antipsychotic prescription among adolescents with bipolar disorder.
    Patel NC; DelBello MP; Keck PE; Strakowski SM
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):938-46. PubMed ID: 16379514
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.
    Dusetzina SB; Cook BL; Busch AB; Alexander GC; Huskamp HA
    Psychiatr Serv; 2013 Jan; 64(1):83-7. PubMed ID: 23280461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effects of race and comorbidity on clinical diagnosis in patients with psychosis.
    Strakowski SM; Shelton RC; Kolbrener ML
    J Clin Psychiatry; 1993 Mar; 54(3):96-102. PubMed ID: 8096843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospective study of neuroleptic-induced dystonia in mania and schizophrenia.
    Khanna R; Das A; Damodaran SS
    Am J Psychiatry; 1992 Apr; 149(4):511-3. PubMed ID: 1348162
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ethnicity and symptom expression in patients with acute schizophrenia.
    Chang N; Newman J; D'Antonio E; McKelvey J; Serper M
    Psychiatry Res; 2011 Feb; 185(3):453-5. PubMed ID: 20705345
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices.
    Peralta V; Cuesta MJ; Caro F; Martinez-Larrea A
    Acta Psychiatr Scand; 1994 Nov; 90(5):354-7. PubMed ID: 7872040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.
    Shriqui CL
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S38-48. PubMed ID: 8564916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence and outcome of schizophrenia in whites, African-Caribbeans and Asians in London.
    Bhugra D; Leff J; Mallett R; Der G; Corridan B; Rudge S
    Psychol Med; 1997 Jul; 27(4):791-8. PubMed ID: 9234457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clozapine utilization and outcomes by race in a public mental health system: 1994-2000.
    Kelly DL; Dixon LB; Kreyenbuhl JA; Medoff D; Lehman AF; Love RC; Brown CH; Conley RR
    J Clin Psychiatry; 2006 Sep; 67(9):1404-11. PubMed ID: 17017827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cross-ethnic symptom differences in schizophrenia: the influence of culture and minority status.
    Brekke JS; Barrio C
    Schizophr Bull; 1997; 23(2):305-16. PubMed ID: 9165639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.
    Stauffer VL; Sniadecki JL; Piezer KW; Gatz J; Kollack-Walker S; Hoffmann VP; Conley R; Durell T
    BMC Psychiatry; 2010 Nov; 10():89. PubMed ID: 21047395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patients with schizophrenia at risk for excessive antipsychotic dosing.
    Walkup JT; McAlpine DD; Olfson M; Labay LE; Boyer C; Hansell S
    J Clin Psychiatry; 2000 May; 61(5):344-8. PubMed ID: 10847308
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gender and ethnic differences in the timing of first sexual intercourse.
    Upchurch DM; Levy-Storms L; Sucoff CA; Aneshensel CS
    Fam Plann Perspect; 1998; 30(3):121-7. PubMed ID: 9635260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decreased urinary peptide excretion in schizophrenic patients after neuroleptic treatment.
    Reichelt KL; Teigland-Gjerstad B
    Psychiatry Res; 1995 Sep; 58(2):171-6. PubMed ID: 8570770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Sequence in prescribing neuroleptics: a therapeutic alternative in refractory schizophrenia?].
    Allouche G; Joober R; Vanelle JM; Brochier T; Olié JP
    Encephale; 1994; 20(6):777-80. PubMed ID: 7875112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Race, Ethnicity, and Self-Rated Health Among Immigrants in the United States.
    Alang SM; McCreedy EM; McAlpine DD
    J Racial Ethn Health Disparities; 2015 Dec; 2(4):565-72. PubMed ID: 26863562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.